Harness Therapeutics Advances First‑in‑Class Huntington’s Disease Candidate HRN001 and Forms Expert Clinical Advisory Board
As reported on PharmaBiz, Harness Therapeutics has selected HRN001 as its lead therapeutic candidate for Huntington’s disease (HD), marking a major milestone for the company as it prepares to transition…